Pra Consultancy company information, Employees & Contact Information

Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium GlobeNewswire

Tumor antigen PRAME promotes melanoma growth by inactivating p53 through the SIRT1-DBC1 axis | Oncogene Nature

Immatics Appoints New CFO to Drive PRAME Therapy Commercialization TipRanks

Combined immunohistochemistry of PRAME and p16 in the differentiation of melanocytic neoplasms, with a detailed focus on acral lesions BioMed Central

Rasmus Faber – Pra Mim – Farplane Records Electronic Groove

Immatics: Taking Off On A PRAME Rocketship Seeking Alpha

Horizon Bancorp names new CEO; Dwight to retire Northwest Indiana Business Magazine

No PRAME encore for Immatics | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial | Nature Medicine Nature

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma GlobeNewswire

PRAME boosts T-cell tumor immunity in specific HLA phenotypes and promotes breast cancer stemness via CCL18 chemokine signaling ScienceDirect.com

Novel PRAME-targeted TCR NK cell therapy receives FDA IND clearance for hematologic cancers MD Anderson Cancer Center

Promising Results for IMA203 in Melanoma: A PRAME-Targeted Trial Targeted Oncology

PRAME-Targeted Agent Shows Activity in Pretreated Metastatic Melanoma CancerNetwork

Immatics’ PRAME gift keeps on giving | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

FDA Clears IND of PRAME TCR-IL-15 NK Program for R/R Myeloid Malignancies Targeted Oncology

PRAME expression in fibrosarcomatous dermatofibrosarcoma protuberans Nature

Immatics builds on its PRAME success | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

PRAME induces genomic instability in uveal melanoma Nature

WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy | Leukemia Nature

Potent and Target Specific Cytotoxicity of PRAME TCR Mimic CAR T Cells in KMT2A-Rearranged AML Patient-Derived Xenograft Model ScienceDirect.com

Intrinsic disorder in PRAME and its role in uveal melanoma Cell Communication and Signaling

Replay wins IND clearance for PRAME T cell cancer therapy Clinical Trials Arena

PRAME Expression in Melanocytic Proliferations in Special Sites MDEdge

CIC::DUX4 Sarcoma With Preferentially Expressed Antigen in Melanoma (PRAME) Immunopositivity Cureus

Integrated 15-GEP and PRAME Classifier Shows Prognostic Accuracy in Uveal Melanoma OncLive

ASCO: Immatics PRAME cell therapy tied to 56% response rate in melanoma study Fierce Biotech

Targeting PRAME for acute myeloid leukemia therapy Frontiers

PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer Frontiers

Investigation of PRAME expression in lipid‐laden and non‐lipid‐laden cutaneous histiocytes Wiley Online Library

Immatics Announces Second Quarter 2025 Financial Results and Business Update GlobeNewswire

PRAME expression in spindle cell melanoma, malignant peripheral nerve sheath tumour, and other cutaneous sarcomatoid neoplasms: a comparative analysis Wiley Online Library

PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer Journal of Translational Medicine

Immatics' solid tumor data fan PRAME flame, sending stock soaring Fierce Biotech

The utility of PRAME staining in identifying malignant transformation of melanocytic nevi Wiley Online Library

PRAME is a useful marker for the differential diagnosis of melanocytic tumours and histological mimics Wiley Online Library

Tumor-associated antigen Prame targets tumor suppressor p14/ARF for degradation as the receptor protein of CRL2 Nature

PRAME immunohistochemistry compared to traditional FISH testing in spitzoid neoplasms and other difficult to diagnose melanocytic neoplasms Frontiers

Diagnostic test accuracy meta-analysis of PRAME in distinguishing primary cutaneous melanomas from benign melanocytic lesions Wiley Online Library

A novel member of Prame family, Gm12794c , counteracts retinoic acid differentiation through the methyltransferase activity of PRC2 Nature

Clinical implication of PRAME immunohistochemistry in differentiating melanoma in situ and dysplastic nevus in non-acral nevus-associated melanoma in situ: An institutional experience and meta-analysis Wiley Online Library

Cyclin D1 and PRAME expression in distinguishing melanoma in situ from benign melanocytic proliferation of the nail unit BioMed Central

Performance of preferentially expressed antigen in melanoma (PRAME) immunohistochemistry for metastatic melanoma in cytology specimens Wiley Online Library

PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features Wiley Online Library

Aberrant expression of HMB45 and negative PRAME expression in halo nevi Wiley Online Library

Cancer testis antigen PRAME: An anti‐cancer target with immunomodulatory potential Wiley Online Library

Immatics Announces First Quarter 2025 Financial Results and Business Update GlobeNewswire

PRAME immunohistochemistry is useful in the evaluation of conjunctival melanomas, nevi, and primary acquired melanosis Wiley Online Library

Utility of PRAME staining in identifying malignant transformation of melanocytic nevi Dermatology Times

Diffuse PRAME expression is highly specific for malignant melanoma in the distinction from clear cell sarcoma Wiley Online Library

Roche’s anti-PRAME antibody launched in China for melanoma diagnosis BioWorld MedTech

T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting Demonstrating a Potential Best-in-Class PRAME Targeted TCR-T Therapy GlobeNewswire

PRAME expression in cellular neurothekeoma: A study of 11 cases - Cesinaro - 2022 - Journal of Cutaneous Pathology Wiley Online Library

Expression and prognostic relevance of PRAME in primary osteosarcoma ScienceDirect.com

PRAME expression in melanocytic lesions of the conjunctiva - Šekoranja - 2021 - Histopathology Wiley Online Library

Immatics Announces Updated Phase 1b Clinical Data on GlobeNewswire

The cancer/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas Nature

Immunocore’s Brenetafusp: A Promising Study in PRAME-Positive Cancers TipRanks

Replay’s oncology-focused product company Syena and Miltenyi Biotec enter into exclusive licensing and GMP manufacturing agreement for PRAME TCR-NK cell therapy based on CliniMACS Prodigy® GlobeNewswire

(PDF) Tumor associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B-cell lymphoma researchgate.net

Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma Nature

Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma Nature

Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia ScienceDirect.com

PRAME expression and clinical outcome of breast cancer Nature